- Home
- MAC vs GH Comparison
MAC vs GH Comparison
Compare MAC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- GH
- Stock Information
- Founded
- MAC 1964
- GH 2011
- Country
- MAC United States
- GH United States
- Employees
- MAC N/A
- GH N/A
- Industry
- MAC Real Estate Investment Trusts
- GH Medical Specialities
- Sector
- MAC Real Estate
- GH Health Care
- Exchange
- MAC Nasdaq
- GH Nasdaq
- Market Cap
- MAC 5.1B
- GH 6.1B
- IPO Year
- MAC 1994
- GH 2018
- Fundamental
- Price
- MAC $19.83
- GH $42.87
- Analyst Decision
- MAC Hold
- GH Strong Buy
- Analyst Count
- MAC 12
- GH 18
- Target Price
- MAC $18.55
- GH $44.88
- AVG Volume (30 Days)
- MAC 1.4M
- GH 2.3M
- Earning Date
- MAC 02-27-2025
- GH 02-20-2025
- Dividend Yield
- MAC 3.42%
- GH N/A
- EPS Growth
- MAC N/A
- GH N/A
- EPS
- MAC 0.36
- GH N/A
- Revenue
- MAC $788,288,000.00
- GH $739,016,000.00
- Revenue This Year
- MAC N/A
- GH $33.18
- Revenue Next Year
- MAC $2.59
- GH $16.41
- P/E Ratio
- MAC $55.50
- GH N/A
- Revenue Growth
- MAC N/A
- GH 31.04
- 52 Week Low
- MAC $12.99
- GH $15.81
- 52 Week High
- MAC $22.27
- GH $50.89
- Technical
- Relative Strength Index (RSI)
- MAC 42.29
- GH 45.70
- Support Level
- MAC $20.27
- GH $47.03
- Resistance Level
- MAC $20.97
- GH $49.90
- Average True Range (ATR)
- MAC 0.53
- GH 2.62
- MACD
- MAC -0.07
- GH -0.60
- Stochastic Oscillator
- MAC 13.33
- GH 13.32
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.